Replies to post #236703 on Biotech Values

[DewDiligence]

ENTA—COVID pandemics will be over before they start PhII.

ENTA acknowledges that, which is why they’re allocating very modest resources to the COVID-19 program. Still, there could end up being a long-lasting market for COVID-19 antivirals, so this program seems to have a reasonable cost/benefit tradeoff.